Virginia Carden Carnahan, Vertex Pharmaceuticals
I got my first taste of this industry as an intern at Schering-Plough's Managed Care group.
Virginia Carden Carnahan
Vice President, New Product Planning and Strategy, Vertex Pharmaceuticals
I got my first taste of this industry as an intern at Schering-Plough's Managed Care group. After finishing my MBA at Duke University's Fuqua School of Business, I joined Schering Plough's oncology marketing team for Intron A. Afterward, I took a field sales rotation during the launch of Claritin. The field experience helped me to better understand which marketing strategies help deliver data clearly to physicians and patients.
Now I head up the New Product Planning and Strategy group at Vertex Pharmaceuticals. Essentially, we are interpreters. We collect customer insights, unmet needs, and communicate these to the research and development organizations within Vertex. This helps to shape the discovery and development of compounds that are aligned with the unmet needs of patients.
The pharma industry must discover new ways to address patient needs with new medicines, and ensure that they are accessible to those patients. To ensure that access, we need to develop strong value propositions for payers to complement the benefit/risk ratio for patients and physicians. Industry also needs to address the changing environment, and the current lack of trust between our industry and society. We need to rethink our strategies, and that may require new leadership to challenge the traditional approach.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
